Company / SG&A Expense
Twist Bioscience Corp SG&A Expense History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$247.0M
FY2025
5-year range
$135.9M / $247.0M
FY2021-FY2025
Trend
+13.1%
vs FY2024
Sector context
#63 of 211
Health Care
What the data says
At $247M, Twist Bioscience Corp's sg&a expense ranks #149 of 211 in the Health Care sector. Increased from $190M to $247M over the past 2 years.
Based on SEC 10-K filings.
$247M in FY2025 with a 5-year CAGR of +19.1%.
Increased from $190M to $247M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +5.1%
- 5-Year CAGR
- +19.1%
- 10-Year CAGR
- -
Sector benchmark
#149 of 211 in Health CareTop 70% of 211This company $247.0M Sector average $728.7M
▼
-66.1% below sector average
Key checks
Key Insights
- 5-year CAGR of +19.1%, indicating consistent growth.
- In FY2025, sg&a expense increased 13.1% year-over-year.
- Ranks #63 out of 211 companies in the Health Care sector.
- Lowest sg&a expense in the period was in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.79 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $247.0M | +13.1% |
| FY2024 | $218.4M | +15.1% |
| FY2023 | $189.7M | -10.9% |
| FY2022 | $212.9M | +56.7% |
| FY2021 | $135.9M | +31.6% |
| FY2020 | $103.3M | +28.9% |
| FY2019 | $80.1M | +84.4% |
| FY2018 | $43.5M | +66.7% |
| FY2017 | $26.1M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026